What is the recommended treatment for complex regional pain syndrome (CRPS)?

Treatment of Complex Regional Pain Syndrome

Complex regional pain syndrome requires a multimodal treatment strategy centered on early physical rehabilitation combined with pharmacologic interventions, with bisphosphonates as first-line pharmacotherapy for inflammatory subtypes and spinal cord stimulation reserved for refractory cases.

Core Treatment Framework

The foundation of CRPS management rests on three pillars that should be initiated simultaneously:

1. Physical and Restorative Therapy (First-Line, Mandatory)

Physical therapy must begin immediately upon diagnosis and serves as the cornerstone of treatment 1. The approach should include:

• Progressive tactile desensitization to address hyperalgesia and allodynia
• Active range-of-motion exercises to prevent contractures and maintain function
• Edema management through elevation and compression
• Normalization of movement patterns to restore limb function 2

Critical pitfall: Prolonged immobilization worsens outcomes. Avoid extended rest periods even when pain is severe 3.

2. Pharmacologic Management (Subtype-Dependent)

The medication strategy should be tailored to the predominant CRPS subtype:

For Inflammatory Subtype (Early-Stage CRPS):

• Bisphosphonates (parenteral): First-line agent with strongest evidence, reducing pain scores by 23.8 points on VAS/NRS compared to placebo 4. This represents the highest quality evidence for any single pharmacologic agent in CRPS 5.
• Corticosteroids: Consider for early inflammatory features 2

For Neuropathic/Nociplastic Subtype:

• Anticonvulsants (gabapentin, pregabalin): Use as part of multimodal strategy 1
• Tricyclic antidepressants or SNRIs (amitriptyline, duloxetine, venlafaxine): Should be included in multimodal approach 1
• Ketamine: Reduces VAS/NRS pain scores by 8.27 points; effective for neuropathic component 4, 5

For Vasomotor Subtype:

• Sympathetic nerve blocks: Effective for addressing vasomotor disturbances 5

Adjunctive Medications:

• Topical agents (lidocaine, capsaicin, ketamine): Use for peripheral neuropathic pain component 1
• Extended-release opioids: May be used as part of multimodal strategy, though not first-line 1
• NSAIDs: Can be incorporated but limited evidence specific to CRPS 1

Important caveat: No medications are FDA-approved specifically for CRPS 2. All pharmacologic interventions are off-label but supported by evidence from neuropathic pain literature.

3. Psychological Interventions (Essential Component)

Psychological treatment is not optional—it should be integrated from the outset:

• Cognitive behavioral therapy: Provides pain relief with evidence from RCTs showing benefit up to 2 years 1
• Biofeedback and relaxation training: Effective for chronic pain management 1
• Supportive psychotherapy or group therapy: Should be offered to all patients 1

Interventional Treatments for Refractory Cases

When conservative measures prove insufficient after 3-6 months, escalate to interventional approaches:

Neuromodulation (Strongest Evidence for Refractory CRPS):

• Spinal cord stimulation: May be used for persistent radicular pain and CRPS not responding to other therapies, with pain reduction up to 70% 1, 6. Requires trial stimulation before permanent implantation 1.

• Dorsal root ganglion (DRG) stimulation: Demonstrates 43-82% pain reduction with improvement in quality of life 6. Particularly effective due to multimechanistic properties across all CRPS subtypes 5.

• Peripheral nerve stimulation: Consider for painful peripheral nerve injuries unresponsive to other treatments 1

Critical requirement: Shared decision-making must include specific discussion of complications before any neuromodulation procedure 1.

Sympathetic Blockade:

• Stellate ganglion or lumbar sympathetic blocks: Use to support diagnosis of sympathetically maintained pain and provide therapeutic benefit for vasomotor symptoms 1, 6
• Evidence shows varying efficacy levels; best used as diagnostic tool and temporary relief measure 6

Epidural Interventions:

• Epidural steroid injections: May be used for radicular pain component as part of multimodal regimen 1
• Transforaminal approach requires image guidance to confirm needle position 1

End-Stage Motor Disturbances:

• Intrathecal baclofen: Reserved for severe, refractory motor disturbances 5
• Intrathecal opioid infusion: May be considered for neuropathic pain, with mandatory discussion of complications 1

Treatment Algorithm

Immediate (Week 1):

1. Initiate physical therapy with desensitization and active movement
2. Start bisphosphonates (if inflammatory subtype/early stage)
3. Begin psychological support

Early Phase (Weeks 2-12):

1. Add anticonvulsants and/or antidepressants for neuropathic features
2. Consider topical agents for localized symptoms
3. Continue aggressive physical rehabilitation
4. Trial sympathetic blocks if vasomotor symptoms predominate

Intermediate Phase (3-6 months):

1. If pain prevents rehabilitation participation, refer to pain specialist
2. Consider ketamine infusion for severe neuropathic pain
3. Evaluate for neuromodulation trial if symptoms remain refractory

Chronic/Refractory Phase (>6 months):

1. Trial spinal cord or DRG stimulation
2. Consider intrathecal therapies for severe cases
3. Maintain physical therapy and psychological support throughout

Critical Pitfalls to Avoid

• Delayed diagnosis and treatment: Outcomes improve dramatically with early intervention 2, 3
• Monotherapy approach: CRPS requires multimodal treatment; single interventions rarely succeed 1
• Premature diagnosis: CRPS is a diagnosis of exclusion; rule out alternative surgical conditions first 3, 7
• Neglecting psychological factors: Pain catastrophizing and psychological distress significantly impact outcomes 8
• Prolonged immobilization: Worsens dystrophy and functional outcomes 3
• Failure to monitor medication compliance and side effects: Establish monitoring strategy before initiating long-term pharmacotherapy 1

Monitoring Strategy

Before prescribing any long-term pharmacologic therapy, establish a strategy for monitoring side effects, adverse effects, and compliance 1. Include periodic follow-up evaluations as part of the overall long-term treatment strategy 1.